GoodRx Forecasts 2024 Revenue Of $800M-$810M Versus Consensus Of $857.80M, With Adjusted EBITDA Over $250M
Portfolio Pulse from Benzinga Newsdesk
GoodRx has projected its 2024 revenue to be between $800M-$810M, which is below the consensus estimate of $857.80M. However, the company expects its adjusted EBITDA to exceed $250M.
May 09, 2024 | 10:54 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
GoodRx's 2024 revenue forecast is below market expectations, but it anticipates a strong adjusted EBITDA over $250M.
GoodRx's revenue forecast being lower than the consensus estimate may lead to negative investor sentiment in the short term, potentially impacting the stock price negatively. However, the strong EBITDA projection could mitigate some concerns by indicating operational efficiency and profitability.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100